Top Medical Searches

Johnson & Johnson drug succeeds in newly diagnosed multiple myeloma patients: study

(Reuters) – Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

 Read more…

Be Sociable, Share!
November 21st, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us